Efficacy and safety of platelet additive solution‐E stored platelet concentrates

Abstract

AbstractIntroductionIn 2018, platelet (PLT) additive solution‐E (PAS‐E) was introduced. The implementation of PAS‐E was expected to diminish the number of allergic reactions in recipients following a PLT transfusion. Here, we evaluated the efficacy and safety of transfusions with PLTs stored in PAS‐E.Study Design and MethodsAfter implementation of PAS‐E, data were collected from 2 cohorts of patients with hematological disorders as well as oncology patients, receiving PLTs in PAS‐E. A similar patient group in a recent RCT, receiving PLTs in plasma, was used as a historical control group for both cohorts. Endpoints were corrected count increments (CCIs), bleeding scores (only reported in cohort 1), and the incidence of adverse reactions.ResultsIn cohort 1, the mean 1‐h CCI was 14.3 ± 6.9, and the 24‐h CCI was 8.7 ± 5.6. In cohort 2, the 1‐h CCI was 11.6 ± 7.8 and the 24‐h CCI was 7.0 ± 6.1. In the control group, the 1‐h CCI was 15.4 ± 5.5 and 24‐h CCI 8.7 ± 4.8. Bleeding complications of WHO grade ≥2 occurred in 40% of patients in cohort 1 compared to 44% in plasma PCs. The incidence of adverse reactions was 1.2% in the two PAS‐E cohorts, compared to 3.0% in plasma PCs. National hemovigilance data showed a significant reduction in allergic reactions with PAS‐E PC transfusions as compared to plasma PCs with an odds ratio of 0.46 (CI 95% 0.37–0.58).ConclusionThe CCIs of PLTs in PAS‐E were decreased compared to plasma PCs, but clinically acceptable. Allergic transfusion reactions were decreased in PAS‐E PCs compared to plasma PCs.